1. Home
  2. CABA vs GRRR Comparison

CABA vs GRRR Comparison

Compare CABA & GRRR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cabaletta Bio Inc.

CABA

Cabaletta Bio Inc.

HOLD

Current Price

$2.70

Market Cap

495.7M

Sector

Health Care

ML Signal

HOLD

Logo Gorilla Technology Group Inc.

GRRR

Gorilla Technology Group Inc.

HOLD

Current Price

$12.13

Market Cap

330.0M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
CABA
GRRR
Founded
2017
2001
Country
United States
United Kingdom
Employees
N/A
200
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
495.7M
330.0M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
CABA
GRRR
Price
$2.70
$12.13
Analyst Decision
Strong Buy
Analyst Count
6
0
Target Price
$14.50
N/A
AVG Volume (30 Days)
4.6M
1.4M
Earning Date
05-14-2026
06-17-2026
Dividend Yield
N/A
N/A
EPS Growth
10.26
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$69.35
Revenue Next Year
N/A
$85.38
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.26
$9.04
52 Week High
$4.23
$23.49

Technical Indicators

Market Signals
Indicator
CABA
GRRR
Relative Strength Index (RSI) 39.67 33.25
Support Level $2.37 $11.53
Resistance Level $2.70 $13.39
Average True Range (ATR) 0.19 1.31
MACD -0.01 -0.47
Stochastic Oscillator 14.62 16.79

Price Performance

Historical Comparison
CABA
GRRR

About CABA Cabaletta Bio Inc.

Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.

About GRRR Gorilla Technology Group Inc.

Gorilla Technology Group Inc is engaged in providing information, software, and data processing services. It is a provider of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology (OT) security solutions and services. Its reportable segments are video IoT and security convergence and Other segments. Its expertise lies in revolutionizing urban operations, enhancing security, and optimizing digital transformation. It delivers pioneering products that integrate AI, deep learning, and edge computing to advance intelligent video surveillance, facial recognition, license plate recognition, post-event analytics, cybersecurity, and network intelligence.

Share on Social Networks: